| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,115 | 0,126 | 17.11. | |
| 0,111 | 0,127 | 17.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | 1.204 | ACCESS Newswire | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| 23.09. | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | 1.199 | ACCESS Newswire | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| 17.09. | Onco-Innovations Ltd: Onco-Innovations issues 860,168 shares for debt | 56 | Stockwatch | ||
| 16.09. | Onco-Innovations Limited: Onco-Innovations Announces Closing of Shares for Debt Settlement | 12 | TheNewswire | ||
| 10.09. | Onco-Innovations Limited: Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species | 64 | TheNewswire | ||
| ONCO-INNOVATIONS Aktie jetzt für 0€ handeln | |||||
| 09.09. | Onco-Innovations Limited: Onco-Innovations Announces Shares for Debt Settlement | 35 | TheNewswire | ||
| 20.08. | Onco-Innovations Ltd: Onco-Innovations enters LOI for LAG-3 option | 52 | Stockwatch | ||
| 20.08. | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | 993 | ACCESS Newswire | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| 13.08. | Onco-Innovations Limited: Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update | 50 | TheNewswire | ||
| 31.07. | Onco-Innovations Limited: Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010 | 70 | TheNewswire | ||
| 29.07. | Onco-Innovations Limited: Onco-Innovations Announces Initial Closing of Notional CAD$5 Million Performance-Based Funding Arrangement | 11 | TheNewswire | ||
| 28.07. | Onco-Innovations Ltd: Onco-Innovations reprices financing with Sorbie | 31 | Stockwatch | ||
| 27.07. | Onco-Innovations Limited: Onco-Innovations Announces Repricing of Previously Announced Performance-Based Funding Arrangement | 6 | TheNewswire | ||
| 17.07. | Onco-Innovations Ltd: Onco-Innovations begins studies to develop ONC010 | 16 | Stockwatch | ||
| 17.07. | Onco-Innovations Limited: Onco-Innovations Initiates ADME Studies Supporting Development of ONC010 | 7 | TheNewswire | ||
| 16.07. | Onco-Innovations Ltd: Onco-Innovations obtains $280,000 in loans | 12 | Stockwatch | ||
| 16.07. | Onco-Innovations Limited: Onco-Innovations Announces Entry into Loan Agreements | 4 | TheNewswire | ||
| 11.07. | Onco-Innovations Ltd: Onco completes preparation program for A83B4C63 | 11 | Stockwatch | ||
| 11.07. | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | 1.042 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| 01.07. | Onco-Innovations Limited: Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing | 1.019 | ACCESS Newswire | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Company")... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,15 | 0,00 % | Option auf Zeitgewinn: BioNTech investiert Millionen in möglichen Zulassungsvorsprung | Mit einem Prüfungsgutschein will BioNTech die Entscheidung der US-Arzneimittelbehörde über ein Krebsmedikament um rund vier Monate vorziehen. Damit wären frühere Umsätze möglich, doch Studienrückschläge... ► Artikel lesen | |
| EVOTEC | 2,750 | -6,34 % | Evotec erhält weitere Millionen von der Gates Foundation | Evotec erhält von der Gates Foundation weitere 2,9 Millionen US-Dollar für die Entwicklung neuer Methoden zur Sicherheitsbewertung von Arzneimitteln. Die Förderung erstreckt sich über drei Jahre und... ► Artikel lesen | |
| BB BIOTECH | 57,00 | 0,00 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | -0,24 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 188,04 | 0,00 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| AMGEN | 415,95 | -0,04 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| VALNEVA | 2,559 | -0,85 % | Valneva: Starke Studien, aber der Chart bleibt wacklig - jetzt zählt die nächste Marke | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,200 | -0,41 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| STRYKER | 288,10 | -0,17 % | Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements-and he won't build them in China because 'the IP is a massive worry' | ||
| BIOGEN | 226,05 | -0,83 % | Biogen Inc.: Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease | Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment differenceGreater slowing of clinical decline... ► Artikel lesen | |
| BIOFRONTERA | 2,840 | -3,07 % | Biofrontera AG: Was der Umsatzsprung nicht verrät | ||
| HEIDELBERG PHARMA | 2,040 | 0,00 % | Formycon, Heidelberg Pharma oder Medios: Welche Biotech-Aktie ist jetzt die stärkste? | ||
| ILLUMINA | 183,98 | -0,07 % | Illumina auf der Jefferies Global Healthcare Conference: Wachstum und Margen legen zu |